President Trump’s strategy to curtail the opiod crisis trumpets getting tough on drug dealers and even considers administering the death penalty (“Trump hits Boston in detailing opioid fight,’’ Page A1, March 20). Will this new effort include holding to account executives at Purdue Pharma, the maker of OxyContin, as well as at Insys Therapeutics, Endo Pharmaceuticals, Janssen, Teva, and others? Or are we going to just round up the usual suspects? Follow the trail of opiod devastation and it leads to the boardroom, not the back room.

Todd Goldstein

Attleboro